scholarly journals Vagus nerve stimulation accelerates motor learning through cholinergic modulation

2021 ◽  
Author(s):  
Spencer Bowles ◽  
Jordan Hickman ◽  
Xiaoyu Peng ◽  
W. Ryan Williamson ◽  
Rongchen Huang ◽  
...  

Vagus nerve stimulation (VNS) is a novel therapeutic option to treat a broad and rapidly expanding set of neurologic conditions. While classically used to treat epilepsy and depression, more recently VNS has received FDA approval as a therapeutic option for stroke rehabilitation and is under preclinical and clinical investigation for other disorders. Despite benefits across a diverse range of neurological disorders, the mechanism for how VNS influences central nervous system circuitry is not well described. A deeper understanding of the influence of VNS on neural circuits and activity is needed to optimize the use of VNS therapy. To define the complex dynamics between VNS, neuronal activity, plasticity, and behavior, we performed chronic VNS in mice during the learning of a dexterous motor task, and leveraged genetic tools to perform optogenetic circuit dissection and longitudinal in vivo imaging calcium activity in cortical neurons. We find VNS has the most robust effect on motor learning when paired with successful movement outcome, while randomized stimulation impairs learning, consistent with VNS serving as a reinforcement cue. In motor cortex, VNS paired with movement outcome selectively modulates neurons that are representing outcome, but not other movement-related neurons. Finally, cholinergic signaling from basal forebrain is required both for VNS-driven improvements in motor learning and the effects on neural activity in M1. This suggests that the effect of VNS on motor learning is mediated by cholinergic signaling, and also presents a novel role for cholinergic signaling in endogenous motor learning. These data imply that VNS therapy may be mediated by augmenting reinforcement cues with precisely-timed cholinergic neuronal activity, presenting strategies for optimizing the use of VNS to treat neurologic conditions.

2019 ◽  
Vol 20 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Laura Pérez-Carbonell ◽  
Howard Faulkner ◽  
Sean Higgins ◽  
Michalis Koutroumanidis ◽  
Guy Leschziner

Vagus nerve stimulation (VNS) is a neuromodulatory therapeutic option for drug-resistant epilepsy. In randomised controlled trials, VNS implantation has resulted in over 50% reduction in seizure frequency in 26%–40% of patients within 1 year. Long-term uncontrolled studies suggest better responses to VNS over time; however, the assessment of other potential predictive factors has led to contradictory results. Although initially designed for managing focal seizures, its use has been extended to other forms of drug-resistant epilepsy. In this review, we discuss the evidence supporting the use of VNS, its impact on seizure frequency and quality of life, and common adverse effects of this therapy. We also include practical guidance for the approach to and the management of patients with VNS in situ.


2013 ◽  
Vol 71 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Murilo S. Meneses ◽  
Samanta F. B. Rocha ◽  
Cristiane Simão ◽  
Heraldo Nei Hardt Laroca dos Santos ◽  
Cleudi Pereira ◽  
...  

INTRODUCTION: Refractory epilepsy accounts for 20 to 30% of epilepsy cases and remains a challenge for neurologists. Vagus nerve stimulation (VNS) is an option for palliative treatment. OBJECTIVE: It was to study the efficacy and tolerability of VNS in patients implanted with a stimulator at the Curitiba Institute of Neurology (INC). METHODS: A case study of six patients with refractory epilepsy submitted to a VNS procedure at the INC in the last four years was described and discussed. RESULTS: Mean age at time of implantation was 29 years. Mean follow-up was 26.6 months. Seizure frequency decreased in all patients (40-50% (n=2) and >80% (n=4)). Three patients no longer required frequent hospitalizations. Two patients previously restricted to wheelchairs started to walk, probably because of improved mood. CONCLUSION: In this population, VNS proved to be a sound therapeutic option for treating refractory epilepsy.


2019 ◽  
Vol 28 (04) ◽  
pp. 230-234
Author(s):  
Bruno Toshio Takeshita ◽  
Carolina Oldoni ◽  
Rafaella Do Rosario Tacla ◽  
Karina Slompo ◽  
Camilla Von Steinkirch ◽  
...  

Approximately 33% of patients with epilepsy do not respond to treatment with a single antiepileptic drug. Many of these patients can benefit from neurosurgical treatment. However, not all patients are candidates for surgery, and in these cases vagus nerve stimulation (VNS) presents as a good therapeutic option. Objectives: Evaluation of efficiency, tolerability and safety in the control of seizures after VNS implantation in patients from a reference hospital. Methods: cross-sectional study examined 20 patients who underwent implantation of the VNS in our facilities between 2007 and 2014. Proportions and chi-square test were applied (statistical significance level set to p ≤ 0.05). Results: Mean follow-up was 31.3 months. Seizure frequency decreased in 55% of the patients. Among them, 11 patients believed that VNS had improved their quality of life. The mean reduction reported by other patients was 78.3%. More than 30% reported no adverse effects. About 70% of patients no longer required hospitalizations and 95% reported reduction in the number of hospitalizations. Conclusion: In this population, VNS proved to be a good option in the treatment of refractory epilepsy and also in providing a significant improvement in quality of life, (reduction of seizures and hospitalizations), mood, attention and memory, which directly reflects on their social and cognitive.


2019 ◽  
Vol 155 ◽  
pp. 106159 ◽  
Author(s):  
Masaya Katagiri ◽  
Koji Iida ◽  
Kumatoshi Ishihara ◽  
Dileep Nair ◽  
Kana Harada ◽  
...  

1984 ◽  
Vol 13 (4) ◽  
pp. 565-571 ◽  
Author(s):  
F.C. Barone ◽  
D.L. Armstrong ◽  
M.J. Wayner ◽  
I.Zarco de Coronado

2021 ◽  
Vol 15 ◽  
Author(s):  
Xiao Wu ◽  
Yue Zhang ◽  
Wen-ting Luo ◽  
Run-ru Mai ◽  
Xiao-yan Hou ◽  
...  

Transcutaneous auricular vagus nerve stimulation (taVNS) has been reported to be effective in the treatment of primary insomnia (PI); however, its efficacy varies considerably across individuals for reasons that are unclear. In order to clarify the underlying mechanisms, this study investigated the effects of taVNS on spontaneous neuronal activity and autonomic nervous system function by functional magnetic resonance imaging (fMRI) and measurement of heart rate variability (HRV), respectively, in patients with PI. Forty patients with PI were divided into effective (group A) and ineffective (group B) groups based on their response to taVNS as determined by Pittsburgh Sleep Quality Index score reduction rate (group A ≥ 25% and group B < 25%). Spontaneous neuronal activity was measured by fractional amplitude of low-frequency fluctuations (fALFF) and HRV values and was compared between the two groups as well as before vs after taVNS. We then analyzed the correlations among efficacy of taVNS for 4 weeks, the fALFF and HRV values during continuous taVNS state. The results showed that the HRV parameter values (i.e., root mean square of successive differences, percentage of adjacent NN intervals differing by >50 ms, and high frequency) of group A were higher than those of group B during continuous taVNS state. In the fMRI scan, the fALFF values of the right cerebellum, right medial superior frontal gyrus, and bilateral supplementary motor area—which belong to the sensorimotor network (SMN)—were lower in group A than in group B during continuous taVNS state. The correlation analysis revealed that the efficacy of continuous taVNS and HRV and fALFF values were interrelated. These findings demonstrate that differential regulation of the SMN by the autonomic nervous system may be responsible for inter-individual variations in the efficacy of taVNS and suggest that HRV and fALFF are potential biomarkers for predicting PI patients’ response to taVNS treatment.


1979 ◽  
Vol 4 (3) ◽  
pp. 381-391 ◽  
Author(s):  
F.C. Barone ◽  
M.J. Wayner ◽  
H.U. Aguilar-Baturoni ◽  
R. Guevara-Aguilar

2019 ◽  
Vol 28 (4) ◽  
pp. 1381-1387
Author(s):  
Ying Yuan ◽  
Jie Wang ◽  
Dongyu Wu ◽  
Dahua Zhang ◽  
Weiqun Song

Purpose Severe dysphagia with weak pharyngeal peristalsis after dorsal lateral medullary infarction (LMI) requires long-term tube feeding. However, no study is currently available on therapeutic effectiveness in severe dysphagia caused by nuclear damage of vagus nerve after dorsal LMI. The purpose of the present investigation was to explore the potential of transcutaneous vagus nerve stimulation (tVNS) to improve severe dysphagia with weak pharyngeal peristalsis after dorsal LMI. Method We assessed the efficacy of 6-week tVNS in a 28-year-old woman presented with persisting severe dysphagia after dorsal LMI who had been on nasogastric feeding for 6 months. tVNS was applied for 20 min twice a day, 5 days a week, for 6 weeks. The outcome measures included saliva spitted, Swallow Function Scoring System, Functional Oral Intake Scale, Clinical Assessment of Dysphagia With Wallenberg Syndrome, Yale Pharyngeal Residue Severity Rating Scale, and upper esophagus X-ray examination. Results After tVNS, the patient was advanced to a full oral diet without head rotation or spitting. No saliva residue was found in the valleculae and pyriform sinuses. Contrast medium freely passed through the upper esophageal sphincter. Conclusion Our findings suggest that tVNS might provide a useful means for recovery of severe dysphagia with weak pharyngeal peristalsis after dorsal LMI. Supplemental Material https://doi.org/10.23641/asha.9755438


Sign in / Sign up

Export Citation Format

Share Document